CD8A and neoplasm: In CT26 tumor-bearing mice, ALX148 treatment significantly enhanced the induction of AH1+CD8+ T cells compared to the vehicle control (Fig 7H, p<0.0001) and not in mice harboring MC38 tumors regardless of treatment (Figure B in S4 Fig).